Apixaban to Prevent Venous Thromboembolism in Patients with Cancer - Université de Bretagne Occidentale Access content directly
Journal Articles New England Journal of Medicine Year : 2019

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Marc Carrier
Karim Abou-Nassar
  • Function : Author
Ranjeeta Mallick
  • Function : Author
Silvana Spadafora
  • Function : Author
Katerine Marquis
  • Function : Author
Mateya Trinkaus
  • Function : Author
Anna Tomiak
  • Function : Author
Peter Gross
  • Function : Author
Robert El-Maraghi
  • Function : Author
Glenwood Goss
  • Function : Author
Debra Witham
  • Function : Author

Abstract

Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis.

Dates and versions

hal-02052475 , version 1 (28-02-2019)

Identifiers

Cite

Marc Carrier, Karim Abou-Nassar, Ranjeeta Mallick, Vicky Tagalakis, Sudeep Shivakumar, et al.. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380 (8), pp.711-719. ⟨10.1056/NEJMoa1814468⟩. ⟨hal-02052475⟩
51 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More